Imigran Neo (Sumatriptan)

Sumatriptan works by selectively stimulating serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings. This causes the vessels to constrict and blocks the release of inflammatory neuropeptides, which together reduce migraine pain and associated symptoms.

The appropriate dose of Imigran Neo is determined by a qualified prescriber based on the individual’s medical condition, response to therapy, and any other medications being taken. Patients should follow the dosing instructions provided by their healthcare professional.

Safety of sumatriptan during pregnancy or while breastfeeding has not been fully established. Women who are pregnant, planning to become pregnant, or nursing should discuss potential risks and benefits with their physician before using Imigran Neo.

To place an order, submit an enquiry on the Imigran Neo product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Imigran Neo (sumatriptan) belongs to the triptan class, which is specifically designed for acute migraine relief. Compared with non‑specific analgesics, triptans target serotonin receptors to address the underlying vascular and neurogenic mechanisms of migraine, often providing faster and more complete symptom resolution.

Imigran Neo should be stored at ambient temperature, below 25 °C (77 °F). Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Imigran Neo is taken orally, usually as a tablet, at the first sign of a migraine or cluster headache. The tablet should be swallowed whole with a glass of water and not crushed or chewed, unless otherwise directed by a healthcare professional.

Serious risks include coronary vasospasm, myocardial infarction, stroke, and serotonin syndrome, especially when combined with other serotonergic drugs. Patients should seek immediate medical attention if they experience chest pain, severe headache, visual changes, or signs of an allergic reaction.

Imigran Neo is contraindicated in patients with known hypersensitivity to sumatriptan, uncontrolled hypertension, significant cardiovascular disease (including coronary artery disease), a history of stroke or transient ischemic attack, and in those currently taking ergot alkaloids or monoamine oxidase inhibitors.